All News

Patients with HER2-positive breast cancer benefitted from treatment with Enhertu regardless of brain metastasis.

Among patients with previously treated advanced clear cell renal cell carcinoma (RCC) Welireg continued to show some benefits, though not to overall survival.

Patients with NSCLC did not see a disease-free survival benefit with Imfinzi after surgery compared with taking a placebo.

Looking back at my experience with osteosarcoma, I realized that managing the mental game was half the battle, especially with so much negativity.

From Princess Kate entering ‘a new phase of recovery’ to a Rock and Roll Hall of Famer’s blood cancer announcement, here’s what’s happening in the cancer space this week.

Several drug classes, including immunotherapy, antibody-drug conjugates and PARP inhibitors have helped improve outcomes for gynecologic cancers.

Tecentriq Hybreza, a subcutaneous delivery of the drug, was approved for certain types of sarcoma, in addition to lung, skin and liver cancers.

A Darzalex-based regimen improved MRD negativity rates compared with VRd in patients with newly diagnosed, transplant-eligible multiple myeloma.

As part of the CURE® Educated Patient® Gynecologic Cancers Summit, an expert explained the basics of biomarkers and the questions they raise.

In this Fall issue of CURE, we focus on AYAs with cancer, latest treatments in small cell lung cancer, preparing for a virtual visit and answering common questions about breast cancer.

Some patients with non-small cell lung cancer saw a 49% reduction in the risk of disease progression or death with ivonescimab versus Keytruda.

Patients with non-small cell lung cancer saw a reduction in their risk of recurrence or death after surgery when treated with pre- and postsurgical Opdivo.

Patients can benefit from clinical trials in gynecologic cancers, and knowing that they can advocate for themselves for potential consideration for study enrollment.

Since my diagnosis with multiple myeloma, I try to keep inspired to keep moving forward despite the challenges.

Dr. Debu Tripathy, editor-in-chief of CURE magazine, discusses the advancements made in small cell lung cancer.

Adcetris plus Revlimid/Rituxan significantly improved outcomes versus Revlimid/Rituxan alone in relapsed/refractory lymphoma.

Rybrevant plus Lazcluze, compared with Tagrisso, showed a trend towards favorable overall survival in EGFR-positive advanced non-small cell lung cancer.

With pivotal trial results and an approval from the FDA, the landscape is changing for patients with small cell lung cancer.

A patient with metastatic breast cancer confronts financial toxicity and finds a little glimmer of hope through donating cancer drugs.

Surgery for gynecologic cancers is a common form of treatment, but each surgical approach has its advantages and disadvantages for patients.

Researchers have compared Xtandi and Zytiga head-to-head in the treatment of metastatic castration-resistant prostate cancer.

After being diagnosed with a type of gynecologic cancer, it is essential for patients to understand the molecular makeup of their disease.

During the cancer treatment process, it's important for adolescents and young adults to balance independence while seeking support from loved ones.

Through journaling and connecting with my faith, I was able to embrace everything I was thinking and feeling during colon cancer.

Spleen size, blood counts and symptom burden are some of the factors cancer teams take into account when selecting which of the four JAK inhibitors to treat patient with myelofibrosis.

The recent FDA approval of Lazcluze plus Rybrevant for EGFR-mutant non-small cell lung cancer is a “big deal” for patients, an oncologist said.

The novel glioblastoma treatment, APTN-101, had its new drug application accepted by the FDA.

I wrote this poem in honor of my niece who had breast cancer, who was determined to live out the rest of her life giving her loved ones hope and strength.